1
|
Benmerzoug S, Chevalier MF, Villier L, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients. EUR UROL SUPPL 2021; 34:79-82. [PMID: 34825225 PMCID: PMC8605422 DOI: 10.1016/j.euros.2021.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/15/2021] [Indexed: 01/03/2023] Open
Abstract
Aberrant glycosylation actively contributes to tumor progression and is a key hallmark of cancer. Most of the glycan moieties expressed on the surface of cancer cells are sialic acids that may modulate antitumor immune responses via binding to sialic acid–binding immunoglobulin-like lectins (Siglecs) expressed by immune cells. Here we show that Siglecs may decrease the bladder tumor immune response mediated by natural killer (NK) cells. We observed higher NK cell activity against desialylated bladder tumor cell lines. We therefore determined the expression of nine Siglecs on circulatory NK cells from healthy donors and patients with bladder cancer (BCa). NK cells from blood mainly express Siglec-7, which is highly upregulated in non–muscle-invasive BCa (NMIBC), as well as Siglec-6, albeit at a much lower level. However, both Siglecs are expressed by urinary NK cells from NMIBC patients undergoing bacillus Calmette-Guérin therapy. Ex vivo analysis of Siglec-6 and Siglec-7 expression levels on tumor-infiltrating NK cells (TINKs) from BCa patients showed that only Siglec-7 is expressed by TINKs. Finally, analyses for The Cancer Genome Atlas data set revealed that BCa patients with high expression levels of Siglec-7 have a poor survival rate. This work indicates that Siglec-7 may restrain NK-mediated antitumor immunity in BCa. Patient summary We investigated the expression of proteins called Siglecs in natural killer (NK) cells from patients with bladder cancer. We showed that levels of the protein Siglec-7 in blood, urine, and tumors from patients with bladder cancer are associated with poor clinical outcomes. Thus, Siglec-7 may be involved in the regulation of antitumor immunity mediated by NK cells in bladder cancer.
Collapse
Affiliation(s)
- Sulayman Benmerzoug
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Mathieu F Chevalier
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.,INSERM U976, Human Immunology, Pathophysiology and Immunotherapy Unit, Hôpital Saint-Louis, Paris, France.,Institut de Recherche Saint Louis, Université de Paris, Hôpital Saint-Louis, Paris, France
| | - Laura Villier
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Sylvain Nguyen
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Valérie Cesson
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Anna K Schneider
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Florence Dartiguenave
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Sonia-Christina Rodrigues-Dias
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Ilaria Lucca
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Patrice Jichlinski
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Beat Roth
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Denise Nardelli-Haefliger
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| | - Laurent Derré
- Department of Urology, Urology Research Unit, Centre Hospitalier Universitaire Vaudois, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
| |
Collapse
|
2
|
Bohner P, Chevalier MF, Cesson V, Rodrigues-Dias SC, Dartiguenave F, Burruni R, Tawadros T, Valerio M, Lucca I, Nardelli-Haefliger D, Jichlinski P, Derré L. Double Positive CD4 +CD8 + T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. Front Immunol 2019; 10:622. [PMID: 30984190 PMCID: PMC6450069 DOI: 10.3389/fimmu.2019.00622] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 03/08/2019] [Indexed: 01/01/2023] Open
Abstract
The immune system plays a central role in cancer development, showing both anti-tumor and pro-tumor activities depending on the immune cell subsets and the disease context. While CD8 T cells are associated with a favorable outcome in most cancers, only T helper type 1 (Th1) CD4 T cells play a protective role, in contrast to Th2 CD4 T cells. Double positive (DP) CD4+CD8+ T cells remain understudied, although they were already described in human cancers, with conflicting data regarding their role. Here, we quantified and phenotypically/functionally characterized DP T cells in blood from urological cancer patients. We analyzed blood leukocytes of 24 healthy donors (HD) and 114 patients with urological cancers, including bladder (n = 54), prostate (n = 31), and kidney (n = 29) cancer patients using 10-color flow cytometry. As compared to HD, levels of circulating DP T cells were elevated in all urological cancer patients, which could be attributed to increased frequencies of both CD4highCD8low and CD4+CD8high DP T-cell subsets. Of note, most CD4highCD8low DP T cells show a CD8αα phenotype, whereas CD4+CD8high cells express both CD8α and CD8β subunits. Functional properties were investigated using ex-vivo generated DP T-cell clones. DP T cells from patients were skewed toward an effector memory phenotype, along with enhanced Th2 cytokine production. Interestingly, both CD8αα and CD8αβ DP T cells were able to trigger Th2 polarization of naïve CD4 T cells, while restraining Th1 induction. Thus, these data highlight a previously unrecognized immunoregulatory mechanism involving DP CD4+CD8+ T cells in urological cancers.
Collapse
Affiliation(s)
- Perrine Bohner
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Mathieu F Chevalier
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Valérie Cesson
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | | | - Florence Dartiguenave
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Rodolfo Burruni
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Thomas Tawadros
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Massimo Valerio
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Ilaria Lucca
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Denise Nardelli-Haefliger
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Patrice Jichlinski
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Laurent Derré
- Urology Research Unit, Urology Department, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| |
Collapse
|